Parallax Volatility Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Parallax Volatility Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-635	Closed	-$41.2K	–	1676
2025 Q3	$41.2K	Sell	635 -6,400	-91%	-$367K	﹤0.01%	1481
2025 Q2	$342K	Buy	+7,035	New	+$272K	﹤0.01%	1254
2023 Q4	–	Sell	-32,646	Closed	-$1.8M	–	2224
2023 Q3	$1.48M	Buy	+32,646	New	+$1.69M	﹤0.01%	1211
2023 Q2	–	Sell	-23,442	Closed	-$1.33M	–	2478
2023 Q1	$1.06M	Buy	+23,442	New	+$1.14M	﹤0.01%	1477
2022 Q4	–	Sell	-7,223	Closed	-$383K	–	2941
2022 Q3	$472K	Buy	+7,223	New	+$523K	﹤0.01%	1997
2022 Q2	–	Sell	-25,445	Closed	-$1.5M	–	2949
2022 Q1	$1.6M	Sell	25,445 -27,892	-52%	-$1.75M	﹤0.01%	1457
2021 Q4	$4.04M	Sell	53,337 -27,730	-34%	-$2.42M	﹤0.01%	1292
2021 Q3	$9.07M	Buy	81,067 +80,827	+33,678%	+$10.2M	0.01%	986
2021 Q2	$39K	Sell	240 -28,331	-99%	-$3.45M	﹤0.01%	2676
2021 Q1	$3.48M	Buy	+28,571	New	+$4.31M	﹤0.01%	1461

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GSK plc London $602M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallax Volatility Advisers's CRSP Position: Q4 2025 in Review

Parallax Volatility Advisers sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 635 shares — an estimated $41.2K sold.

Parallax Volatility Advisers first reported a position in CRSP in Q1 2021 and held it in 10 quarters. The position peaked at $9.07M in Q3 2021. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Parallax Volatility Advisers reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Parallax Volatility Advisers sold 635 CRISPR Therapeutics shares in Q4 2025, an estimated $41.2K.
Parallax Volatility Advisers first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 10 quarters.
Parallax Volatility Advisers's CRISPR Therapeutics position peaked at $9.07M in Q3 2021.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Parallax Volatility Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.